Everest Organics obtains KDMF approval for Rabeprazole Sodium API

18 Feb 2025 Evaluate

Everest Organics has obtained Korea Drug Master File (KDMF) approval for its Rabeprazole Sodium API in the Month of February 2025. The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach; essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux. The company is now able to export its Rabeprazole Sodium API to the South Korean market.  

Everest Organics carry the business of manufacturing of bulk drugs viz. Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Benzimadizole, etc., having its factory at Sadasivpet Medak District Hyderabad. 

Everest Organics Share Price

252.00 2.00 (0.80%)
28-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...